肺癌目前主要以手术、化疗和靶向治疗作为治疗肺癌的主要办法，其中靶向治疗有望成为治疗肺癌最有效的方法。随着对推动肺癌发展的分子变化和基因组生物标志物的理解加深，发现磷脂酰肌醇3-激酶（phosphatidylinositol-3-kinase，PI3K）/蛋白激酶B（protein kinase B，Akt）通路是影响肺癌发生发展的重要一环。该通路是细胞中广泛存在的重要信号通路，激活会导致癌症的多种特征，包括获得性生长信号自主性、细胞凋亡抑制、持续血管新生、组织侵袭和转移增加及对抗生长信号不敏感等，从而调控癌症的进程。天然萜类产物可通过抑制PI3K/Akt通路发挥抗肺癌活性，然而对于此类化合物的研究多停留在体外及体内研究层面，缺乏对这些数据的系统梳理与总结。基于这些现状，就天然萜类产物通过PI3K/Akt信号通路调控肺癌进展的思路进行总结，为探索新型靶向药物和临床治疗肺癌提供相关的理论依据。

At present, lung cancer is mainly treated by surgery, chemotherapy and targeted therapy, among which targeted therapy is expected to be the most effective method. With the increasing understanding of molecular changes and genomic biomarkers that promote the development of lung cancer, it has been found that the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) pathway is an important part of the development of lung cancer. This pathway is an important signaling pathway that is widely present in cells. Activation can lead to a variety of characteristics of cancer, including acquired growth signal autonomy, apoptosis inhibition, continuous angiogenesis, increased tissue invasion and metastasis, and insensitivity to anti-growth signals, thereby regulating the process of cancer. Natural terpenoids can exert anti-lung cancer activity by inhibiting PI3K/Akt pathway. However, the research on such compounds mostly stays at the level of in vitro and in vivo research, and there is a lack of systematic review and summary of these data. Based on these current situations, this review summarizes the current understanding of natural terpenoids in regulating lung cancer progression through the PI3K/Akt signaling pathway, aiming to explore new targeted drugs and provide relevant theoretical basis for clinical treatment of lung cancer.

R285

2025年八桂学者项目（桂人才办[2025]31号）